Online Trial Tracker - Larvol Sigma

dusigitumab (MEDI-573) / AstraZeneca

Welcome, Profile Billing Logout

1 Trials

Active Trials

Trial + Data / Events

Status

Ph

N

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

dusigitumab (MEDI-573) / AstraZeneca

IGF-1: MEDI-573 is in Phase 2 for Breast Cancer

Ongoing

2

0

RoW

MEDI-573

Astrazeneca

Breast cancer

Download Options